*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
The "2024 China Biopharmaceutical Industry Chain Innovation Billboard" was officially announced during the Sixth Session China Biopharmaceutical Industry Innovation and Transformation International Summit & the First Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Industry Innovation and Transformation Forum, grandly held in Guangzhou on December 17, 2024. Azvudine, independently developed by Genuine Biotech, was honored with the "Best Commercial Return Award (Chemical Drug)" for its outstanding performance during its three years on the market.
Recently, the People's Government of Henan Province issued the "Decisions on Science and Technology Awards of Henan Province in 2024", and granted the first prize of Henan Provincial Technical Invention Award to the project "development and application of the Class 1 innovative drug for the dual-target treatment of AIDS" of Azvudine.
On Nov. 28, Genuine Biotech announced that its self-developed Azvudine Tablets (trade name: Jiebeian®) has been successfully renewed in the 2024 National Reimbursement Drug List.
On Oct. 20, the Medical and Health Conference, one of the serial events celebrating the 10th anniversary of Zhongyuan Bank, was successfully held in Zhengzhou. At the conference, Genuine Biotech entered into a strategic cooperation agreement with Zhongyuan Bank, which signifies deepened bank-enterprise cooperation and anticipates to energize the innovation and development in the pharmaceutical industry with technology finance, thereby facilitating scientific & technological innovation and high-quality development of the industry.
Recently, the 2024 Misi Conference (China Medical and Health Industry Symbiosis Conference), organized by the industry's authoritative medical and health information platform MENET, was grandly held in Huzhou, Zhejiang, under the theme "Tenacity·Enlightenment of the New Stage". At the conference, the "2023 Top 100 Innovation List Series for Biopharmaceutical Enterprises in China" was officially released. Genuine Biotech once again made it to the "Top 30 Innovative Small-Molecule Pharmaceutical Enterprises in China", marking the third consecutive year since 2021 that the company has received this honor.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
